BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

239 related articles for article (PubMed ID: 21304526)

  • 1. Hypertension and overall survival in metastatic colorectal cancer patients treated with bevacizumab-containing chemotherapy.
    Österlund P; Soveri LM; Isoniemi H; Poussa T; Alanko T; Bono P
    Br J Cancer; 2011 Feb; 104(4):599-604. PubMed ID: 21304526
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Bevacizumab-induced hypertension as a predictor of clinical outcome in metastatic colorectal cancer: An individual patient data-based pooled analysis of two randomized studies and a systematic review of the literature.
    Lombardi P; Rossini D; Crespi V; Germani MM; Bergamo F; Pietrantonio F; Santini D; Allegrini G; Daniel F; Pagani F; Antoniotti C; Zaniboni A; Conca V; Latiano TP; Boccaccino A; Passardi A; Tamburini E; Masi G; Di Maio M; Cremolini C
    Cancer Treat Rev; 2022 Feb; 103():102326. PubMed ID: 35016085
    [TBL] [Abstract][Full Text] [Related]  

  • 3. A phase II study of high-dose bevacizumab in combination with irinotecan, 5-fluorouracil, leucovorin, as initial therapy for advanced colorectal cancer: results from the Eastern Cooperative Oncology Group study E2200.
    Giantonio BJ; Levy DE; O'dwyer PJ; Meropol NJ; Catalano PJ; Benson AB;
    Ann Oncol; 2006 Sep; 17(9):1399-403. PubMed ID: 16873427
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Hypertension as a predictive biomarker in bevacizumab treatment for colorectal cancer patients.
    Tahover E; Uziely B; Salah A; Temper M; Peretz T; Hubert A
    Med Oncol; 2013 Mar; 30(1):327. PubMed ID: 23254964
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Clinical outcomes associated with bevacizumab-containing treatment of metastatic colorectal cancer: the BRiTE observational cohort study.
    Kozloff M; Yood MU; Berlin J; Flynn PJ; Kabbinavar FF; Purdie DM; Ashby MA; Dong W; Sugrue MM; Grothey A;
    Oncologist; 2009 Sep; 14(9):862-70. PubMed ID: 19726453
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Evaluation of hypertension and proteinuria as markers of efficacy in antiangiogenic therapy for metastatic colorectal cancer.
    Khoja L; Kumaran G; Zee YK; Murukesh N; Swindell R; Saunders MP; Clamp AR; Valle JW; Wilson G; Jayson GC; Hasan J
    J Clin Gastroenterol; 2014; 48(5):430-4. PubMed ID: 24153157
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Bevacizumab-related arterial hypertension as a predictive marker in metastatic colorectal cancer patients.
    De Stefano A; Carlomagno C; Pepe S; Bianco R; De Placido S
    Cancer Chemother Pharmacol; 2011 Nov; 68(5):1207-13. PubMed ID: 21409384
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Safety of bevacizumab treatment in combination with standard chemotherapy for metastatic colorectal cancer: a retrospective review of 65 Japanese patients.
    Tamiya A; Yamazaki K; Boku N; Machida N; Kojima T; Taku K; Yasui H; Fukutomi A; Hironaka S; Onozawa Y
    Int J Clin Oncol; 2009 Dec; 14(6):513-7. PubMed ID: 19967487
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Early hypertension and neutropenia are predictors of treatment efficacy in metastatic colorectal cancer patients administered FOLFIRI and vascular endothelial growth factor inhibitors as second-line chemotherapy.
    Osumi H; Shinozaki E; Ooki A; Wakatsuki T; Kamiimabeppu D; Sato T; Nakayama I; Ogura M; Takahari D; Chin K; Yamaguchi K
    Cancer Med; 2021 Jan; 10(2):615-625. PubMed ID: 33347731
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Combination chemotherapy with bevacizumab and S-1 for elderly patients with metastatic colorectal cancer (BASIC trial).
    Yoshida M; Muro K; Tsuji A; Hamamoto Y; Yoshino T; Yoshida K; Shirao K; Miyata Y; Takahari D; Takahashi T; Ohtsu A
    Eur J Cancer; 2015 May; 51(8):935-41. PubMed ID: 25837882
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Chemotherapy, bevacizumab, and cetuximab in metastatic colorectal cancer.
    Tol J; Koopman M; Cats A; Rodenburg CJ; Creemers GJ; Schrama JG; Erdkamp FL; Vos AH; van Groeningen CJ; Sinnige HA; Richel DJ; Voest EE; Dijkstra JR; Vink-Börger ME; Antonini NF; Mol L; van Krieken JH; Dalesio O; Punt CJ
    N Engl J Med; 2009 Feb; 360(6):563-72. PubMed ID: 19196673
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Arterial hypertension correlates with clinical outcome in colorectal cancer patients treated with first-line bevacizumab.
    Scartozzi M; Galizia E; Chiorrini S; Giampieri R; Berardi R; Pierantoni C; Cascinu S
    Ann Oncol; 2009 Feb; 20(2):227-30. PubMed ID: 18842611
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Predictive value of VEGF gene polymorphisms for metastatic colorectal cancer patients receiving first-line treatment including fluorouracil, irinotecan, and bevacizumab.
    Formica V; Palmirotta R; Del Monte G; Savonarola A; Ludovici G; De Marchis ML; Grenga I; Schirru M; Guadagni F; Roselli M
    Int J Colorectal Dis; 2011 Feb; 26(2):143-51. PubMed ID: 21188390
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Biomarkers of anti-angiogenic therapy in metastatic colorectal cancer (mCRC): original data and review of the literature.
    Pohl M; Werner N; Munding J; Tannapfel A; Graeven U; Nickenig G; Schmiegel W; Reinacher-Schick A
    Z Gastroenterol; 2011 Oct; 49(10):1398-406. PubMed ID: 21964893
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Retrospective cohort study on the safety and efficacy of bevacizumab with chemotherapy for metastatic colorectal cancer patients: the HGCSG0801 study.
    Sogabe S; Komatsu Y; Yuki S; Kusumi T; Hatanaka K; Nakamura M; Kato T; Miyagishima T; Hosokawa A; Iwanaga I; Sakata Y; Asaka M
    Jpn J Clin Oncol; 2011 Apr; 41(4):490-7. PubMed ID: 21303790
    [TBL] [Abstract][Full Text] [Related]  

  • 16. The McCAVE Trial: Vanucizumab plus mFOLFOX-6 Versus Bevacizumab plus mFOLFOX-6 in Patients with Previously Untreated Metastatic Colorectal Carcinoma (mCRC).
    Bendell JC; Sauri T; Gracián AC; Alvarez R; López-López C; García-Alfonso P; Hussein M; Miron ML; Cervantes A; Montagut C; Vivas CS; Bessudo A; Plezia P; Moons V; Andel J; Bennouna J; van der Westhuizen A; Samuel L; Rossomanno S; Boetsch C; Lahr A; Franjkovic I; Heil F; Lechner K; Krieter O; Hurwitz H;
    Oncologist; 2020 Mar; 25(3):e451-e459. PubMed ID: 32162804
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Evaluation of hypertension as a marker of bevacizumab efficacy.
    Ryanne Wu R; Lindenberg PA; Slack R; Noone AM; Marshall JL; He AR
    J Gastrointest Cancer; 2009; 40(3-4):101-8. PubMed ID: 19921473
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Cediranib with mFOLFOX6 versus bevacizumab with mFOLFOX6 as first-line treatment for patients with advanced colorectal cancer: a double-blind, randomized phase III study (HORIZON III).
    Schmoll HJ; Cunningham D; Sobrero A; Karapetis CS; Rougier P; Koski SL; Kocakova I; Bondarenko I; Bodoky G; Mainwaring P; Salazar R; Barker P; Mookerjee B; Robertson J; Van Cutsem E
    J Clin Oncol; 2012 Oct; 30(29):3588-95. PubMed ID: 22965961
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Integrating the anti-VEGF-A humanized monoclonal antibody bevacizumab with chemotherapy in advanced colorectal cancer.
    Hurwitz H
    Clin Colorectal Cancer; 2004 Oct; 4 Suppl 2():S62-8. PubMed ID: 15479481
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Bevacizumab plus irinotecan, fluorouracil, and leucovorin for metastatic colorectal cancer.
    Hurwitz H; Fehrenbacher L; Novotny W; Cartwright T; Hainsworth J; Heim W; Berlin J; Baron A; Griffing S; Holmgren E; Ferrara N; Fyfe G; Rogers B; Ross R; Kabbinavar F
    N Engl J Med; 2004 Jun; 350(23):2335-42. PubMed ID: 15175435
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 12.